MSB (ASX) Ann: Trading Halt

Originally posted by Nikolajxo1: ↑

Diversify Capital Sources– Private placements help diversify a company’s sources of capital and capital structure. The stable investment appetite shown by insurance companies and other large institutional investors in the private placement market is typically independent from many of the market variables that impact bank market lending activity. Since the terms of private placements can be customized, these transactions are typically crafted to complement existing bank credit facility capacity as opposed to directly competing with these relationships. Creating capital access in both the private debt and bank markets can allow companies to optimize their access to debt capital. Diversification of financing sources becomes particularly important during market cycles when bank liquidity may be tight.
Additional Capacity– Many companies issue private placements because they have outgrown their borrowing capacity and need capital beyond what their existing lenders (banks, private equity firms, etc.) can provide. Private placements typically focus on cash flow lending metrics and can be completed on either a secured or unsecured basis, depending on the issuer’s existing capital structure.
Buy-and-Hold– Private placements are typically "buy-and-hold," meaning the debt investment wouldn’t be purchased with the intent to sell to another investor. Thus, private placement borrowers benefit from the ability to create a long-term relationship with the same investor throughout the life of the financing.
Ease of Execution– Private placement financings are regularly completed by both privately-held, middle-market companies as well as large public companies. These transactions provide issuers with access to capital on a scale that rivals underwritten public debt offerings, but without certain preconditional requirements, such as ratings, public registrations or minimum size restrictions. For public companies, private placements can offer superior execution relative to the public market for small issuance sizes as well as greater structural flexibility.
Cost Savings– A company can often issue a private placement for a much lower all-in cost than it could in a public offering. For public issuers, the Security and Exchange Commission (SEC) related registration, legal documentation and underwriting fees for a public offering can be expensive. Additionally, in contrast to banks that often rely on ancillary services and fee generation to enhance investment return, private placement lenders rely exclusively on the yield from the notes that they purchase. Taking into consideration the yield-equivalent savings on avoided underwriting fees, in conjunction with the yield premium often associated with first time issuers and small issuance premiums, private placements can provide a very attractive alternative to the public debt market.
Fewer Investors– Unlike issuing securities on the public market, where companies issuing debt securities often deal with hundreds of investors, private placement transactions typically involve fewer than 10-20 investors, and in many cases, are completed with a single large institutional investor. This approach can materially simplify the investor tracking burden for issuers as well as allow them to concentrate their investor-relationship efforts on a few key financial partners.
Familiar Pricing Process– The process for pricing private placements debt transactions is very similar to that of public securities. The coupon set for fixed-rate notes issued reflects the underlying U.S. Treasury rate corresponding to the tenor of the notes issued, plus a credit risk premium (a “credit spread”). This process allows for general transparency as to the approach that institutional investors undertake when establishing the economics of the transaction.
Speed of Execution– The growth and maturity of the private placement market has led to improved standardization of documentation, visibility of pricing and terms as well as increased capacity for financings. As a result, the private market can accommodate transactions as small as $10 million and as large as $1-$2 billion. That, when combined with standardized documentation and a smaller universe of investors, fosters quick execution of an investment, generally within 6-8 weeks (for an initial transaction, with follow-on financings executed within a shorter time frame). As noted, it can be much faster to issue a private placement versus a public corporate bond (particularly for first-time issuers) due to the elimination of prospectus drafting, rating agency diligence and registering requirements with the SEC.

Expand

Oh, great, in addition to Hot Copper making it hard to format copied articles, now HC is automatically duplicating people's messages when you reply to them. I will delete my post and only include the link here. But it won't help much unless everyone who replied also deletes their post. Just report your own post and say it is at your own request for the reason.

https://www.prudentialprivatecapital.com/perspectives/11-reasons-to-issue-a-private-placement

11 Reasons To Issue A Private Placement

No.	Vol.	Price($)
2	23940	$1.39

No.

Vol.

Price($)

23940

$1.39

Price($)	Vol.	No.
$1.40	22571	2

Price($)

Vol.

No.

$1.40

22571

No.	Vol.	Price($)
2	23940	1.390
3	38984	1.385
4	46804	1.380
2	40933	1.375
3	25278	1.370

No.

Vol.

Price($)

23940

1.390

38984

1.385

46804

1.380

40933

1.375

25278

1.370

Price($)	Vol.	No.
1.395	22571	2
1.400	353114	5
1.405	39000	3
1.410	44610	7
1.415	77894	4

Price($)

Vol.

No.

1.395

22571

1.400

353114

1.405

39000

1.410

44610

1.415

77894

(20min delay)
Last $1.40		Change 0.045(3.33%)		Mkt cap ! $1.592B

Open	High	Low	Value	Volume
$1.35	$1.42	$1.33	$3.802M	2.753M

Ann: Trading Halt, page-48

11 Reasons To Issue A Private Placement

Week 45 Wrap: Combat sports usher in Trump 2.0 – or is it male insecurity?; RBA boring; Propane suggests China alive

Universal Biosensors flat despite fresh deal with US medical product distributor

Imugene kicks off Australian trial for blood cancer treatment

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

Metro Mining inks bauxite offtake contracts into 2026 with Chinese m

Trump is President Again: What Does This Mean for Crypto?

Flynn Gold reaches milestone exploration target for Golden Ridge

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Trump Victory Sends Bitcoin Surging Above $75K – Is $100K Next?

HotCopper Highlights: Your most watched and most discussed stocks this week

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Trading Halt, page-48

11 Reasons To Issue A Private Placement

Top Stories

Week 45 Wrap: Combat sports usher in Trump 2.0 – or is it male insecurity?; RBA boring; Propane suggests China alive

Universal Biosensors flat despite fresh deal with US medical product distributor

Imugene kicks off Australian trial for blood cancer treatment

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

Metro Mining inks bauxite offtake contracts into 2026 with Chinese m

Trump is President Again: What Does This Mean for Crypto?

Flynn Gold reaches milestone exploration target for Golden Ridge

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Trump Victory Sends Bitcoin Surging Above $75K – Is $100K Next?

HotCopper Highlights: Your most watched and most discussed stocks this week

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News